<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiplatelet agents and anticoagulants for hypertension - Shantsila, E - 2022 | Cochrane Library</title> <meta content="Antiplatelet agents and anticoagulants for hypertension - Shantsila, E - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003186.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiplatelet agents and anticoagulants for hypertension - Shantsila, E - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003186.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003186.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antiplatelet agents and anticoagulants for hypertension" name="citation_title"/> <meta content="Eduard Shantsila" name="citation_author"/> <meta content="University of Liverpool and Liverpool Heart &amp; Chest Hospital" name="citation_author_institution"/> <meta content="Monika Kozieł-Siołkowska" name="citation_author"/> <meta content="kozielmonika@poczta.fm" name="citation_author_email"/> <meta content="Gregory YH Lip" name="citation_author"/> <meta content="University of Liverpool and Liverpool Heart &amp; Chest Hospital" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD003186.pub4" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003186.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003186.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003186.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticoagulants [adverse effects]; Aspirin [therapeutic use]; Clopidogrel [therapeutic use]; Fibrinolytic Agents [therapeutic use]; Hemorrhage [chemically induced]; *Hypertension [chemically induced]; Platelet Aggregation Inhibitors [adverse effects]; *Thromboembolism [etiology]; *Thrombosis [prevention &amp; control]; Warfarin [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003186.pub4&amp;doi=10.1002/14651858.CD003186.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="XwNPMGod";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003186\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003186\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","pt","th","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003186.pub4",title:"Antiplatelet agents and anticoagulants for hypertension",firstPublishedDate:"Jul 28, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hypertension Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003186.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003186.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003186.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003186.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003186.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003186.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003186.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003186.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003186.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003186.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5018 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003186.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0087"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-sec-0081"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/appendices#CD003186-sec-0092"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/supinfo/CD003186StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/supinfo/CD003186StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiplatelet agents and anticoagulants for hypertension</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information#CD003186-cr-0004">Eduard Shantsila</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information#CD003186-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Monika Kozieł-Siołkowska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information#CD003186-cr-0006">Gregory YH Lip</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information/en#CD003186-sec-0103">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003186.pub4">https://doi.org/10.1002/14651858.CD003186.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003186-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003186-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003186-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003186-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003186-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003186-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003186-abs-0009">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD003186-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003186-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003186-abs-0001" lang="en"> <section id="CD003186-sec-0001"> <h3 class="title" id="CD003186-sec-0001">Background</h3> <p>The main complications of elevated systemic blood pressure (BP), coronary heart disease, ischaemic stroke, and peripheral vascular disease, are related to thrombosis rather than haemorrhage. Therefore, it is important to investigate if antithrombotic therapy may be useful in preventing thrombosis‐related complications in patients with elevated BP. </p> </section> <section id="CD003186-sec-0002"> <h3 class="title" id="CD003186-sec-0002">Objectives</h3> <p>To conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with elevated BP, including elevations in systolic or diastolic BP alone or together. </p> <p>To assess the effects of antiplatelet agents on total deaths or major thrombotic events or both in these patients versus placebo or other active treatment. </p> <p>To assess the effects of oral anticoagulants on total deaths or major thromboembolic events or both in these patients versus placebo or other active treatment. </p> </section> <section id="CD003186-sec-0003"> <h3 class="title" id="CD003186-sec-0003">Search methods</h3> <p>The Cochrane Hypertension Information Specialist searched the following databases for randomised controlled trials (RCTs) up to January 2021: the Cochrane Hypertension Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 12), Ovid MEDLINE (from 1946), and Ovid Embase (from 1974). The World Health Organization International Clinical Trials Registry Platform and the US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov) were searched for ongoing trials.  </p> </section> <section id="CD003186-sec-0004"> <h3 class="title" id="CD003186-sec-0004">Selection criteria</h3> <p>RCTs in patients with elevated BP were included if they were ≥ 3 months in duration and compared antithrombotic therapy with control or other active treatment. </p> </section> <section id="CD003186-sec-0005"> <h3 class="title" id="CD003186-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data for inclusion criteria, our prespecified outcomes, and sources of bias. They assessed the risks and benefits of antiplatelet agents and anticoagulants by calculating odds ratios (OR), accompanied by the 95% confidence intervals (CI). They assessed risks of bias and applied GRADE criteria.  </p> </section> <section id="CD003186-sec-0006"> <h3 class="title" id="CD003186-sec-0006">Main results</h3> <p>Six trials (61,015 patients) met the inclusion criteria and were included in this review. </p> <p>Four trials were primary prevention (41,695 patients; HOT, JPAD, JPPP, and TPT), and two secondary prevention (19,320 patients, CAPRIE and Huynh). Four trials (HOT, JPAD, JPPP, and TPT) were placebo‐controlled and two studies (CAPRIE and Huynh) included active comparators. </p> <p>Four studies compared acetylsalicylic acid (ASA) versus placebo and found no evidence of a difference for all‐cause mortality (OR 0.97, 95% CI 0.87 to 1.08; 3 studies, 35,794 participants; low‐certainty evidence). We found no evidence of a difference for cardiovascular mortality (OR 0.98, 95% CI 0.82 to 1.17; 3 studies, 35,794 participants; low‐certainty evidence). ASA reduced the risk of all non‐fatal cardiovascular events (OR 0.63, 95% CI 0.45 to 0.87; 1 study (missing data in 3 studies), 2540 participants; low‐certainty evidence) and the risk of all cardiovascular events (OR 0.86, 95% CI 0.77 to 0.96; 3 studies, 35,794 participants; low‐certainty evidence). ASA increased the risk of major bleeding events (OR 1.77, 95% CI 1.34 to 2.32; 2 studies, 21,330 participants; high‐certainty evidence). </p> <p>One study (CAPRIE; ASA versus clopidogrel) included patients diagnosed with hypertension (mean age 62.5 years, 72% males, 95% Caucasians, mean follow‐up: 1.91 years). It showed no evidence of a difference for all‐cause mortality (OR 1.02, 95% CI 0.91 to 1.15; 1 study, 19,143 participants; high‐certainty evidence) and for cardiovascular mortality (OR 1.08, 95% CI 0.94 to 1.26; 1 study, 19,143 participants; high‐certainty evidence). ASA probably reduced the risk of non‐fatal cardiovascular events (OR 1.10, 95% CI 1.00 to 1.22; 1 study, 19,143 participants; high‐certainty evidence) and the risk of all cardiovascular events (OR 1.08, 95% CI 1.00 to 1.17; 1 study, 19,143 participants; high‐certainty evidence) when compared to clopidogrel. Clopidogrel increased the risk of major bleeding events when compared to ASA (OR 1.35, 95% CI 1.14 to 1.61; 1 study, 19,143 participants; high‐certainty evidence). </p> <p>In one study (Huynh; ASA verus warfarin) patients with unstable angina or non–ST‐segment elevation myocardial infarction, with prior coronary artery bypass grafting (CABG) were included (mean age 68 years, 79.8% males, mean follow‐up: 1.1 year). There was no evidence of a difference for all‐cause mortality (OR 0.98, 95% CI 0.06 to 16.12; 1 study, 91 participants; low‐certainty evidence). Cardiovascular mortality, non‐fatal cardiovascular events, and all cardiovascular events were not available. There was no evidence of a difference for major bleeding events (OR 0.13, 95% CI 0.01 to 2.60; 1 study, 91 participants; low‐certainty evidence).  </p> </section> <section id="CD003186-sec-0007"> <h3 class="title" id="CD003186-sec-0007">Authors' conclusions</h3> <p>There is no evidence that antiplatelet therapy modifies mortality in patients with elevated BP for primary prevention. ASA reduced the risk of cardiovascular events and increased the risk of major bleeding events.  </p> <p>Antiplatelet therapy with ASA probably reduces the risk of non‐fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events compared to ASA in patients with elevated BP for secondary prevention.  </p> <p>There is no evidence that warfarin modifies mortality in patients with elevated BP for secondary prevention.  </p> <p>The benefits and harms of the newer drugs glycoprotein IIb/IIIa inhibitors, clopidogrel, prasugrel, ticagrelor, and non‐vitamin K antagonist oral anticoagulants for patients with high BP have not been studied in clinical trials. </p> <p>Further RCTs of antithrombotic therapy including newer agents and complete documentation of all benefits and harms are required in patients with elevated BP. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003186-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003186-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD003186-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD003186-abs-0021">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003186-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003186-abs-0019">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003186-abs-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD003186-abs-0014">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003186-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD003186-abs-0010">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003186-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD003186-abs-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003186-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003186-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003186-abs-0002" lang="en"> <h3>Antiplatelet agents and anticoagulants for high blood pressure (hypertension)</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence that examined whether antiplatelet agents reduced total deaths or major thrombotic events or both in patients with elevated blood pressure (BP) when compared to placebo or other active treatment. We also assessed whether oral anticoagulants reduced total deaths or major thrombotic events or both in these patients when compared to placebo or other active treatment. </p> <p><b>Background</b> </p> <p>Although systemic (arterial) elevations in BP result in high intravascular pressure, the main complications of elevated BP, coronary heart disease events, ischaemic stroke, and peripheral vascular disease, are associated with thrombosis. </p> <p>We wanted to discover whether the use of antithrombotic or antiplatelet therapy may be of particular benefit for primary prevention in reducing total deaths or major thrombotic events or both in patients with elevated BP. Moreover, we tried to determine whether antithrombotic or antiplatelet therapy may be beneficial for secondary prevention in reducing total deaths or major thrombotic events or both in patients with elevated BP. </p> <p><b>Search date</b> </p> <p>This update of a previously published systematic review is current to January 2021.</p> <p><b>Study characteristics</b> </p> <p>We included six trials with a combined total of 61,015 patients in this review. Four trials were primary prevention (41,695 patients; HOT, JPAD, JPPP, and TPT) and two were secondary prevention (19,320 patients; CAPRIE and Huynh). Four trials were placebo‐controlled (HOT, JPAD, JPPP, and TPT) and two trials included active comparators (CAPRIE and Huynh). CAPRIE 1996 included patients from 16 countries in Europe and USA with recent ischaemic stroke, recent myocardial infarction (MI) or symptomatic peripheral vascular disease (PVD). Mean patients' age was 62.5 years. 72% of the patients were males, and 95% of the patients were Caucasians. HOT 1998 included patients from 26 countries, aged 50 to 80 years (mean 61.5 years) with hypertension. In TPT 1998, men aged between 45 and 69 years (mean 57.5 years) at high risk of ischaemic heart disease were recruited from 108 practices in the UK. Huynh 2001 included patients from Canada with mean age of 67 and with unstable angina or non‐ST‐segment elevation MI, with prior coronary artery bypass grafting (CABG), and who were poor candidates for a revascularisation procedure. JPAD 2012 included patients from Japan with type 2 diabetes, mean age 65 years and 55% male. JPPP 2019 included Japanese patients with atherosclerotic risk factors (hypertension, diabetes mellitus, or dyslipidaemia). Median age was 70 years and 42% of patients were men. </p> <p><b>Key results</b> </p> <p>Antiplatelet therapy with acetylsalicylic acid (ASA), also known as aspirin, for primary prevention in patients with elevated BP did not modify mortality and increased the risk of major bleedings. </p> <p>Antiplatelet therapy with aspirin probably reduces the risk of non‐fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events when compared to aspirin in patients with elevated BP for secondary prevention.  </p> <p>There is no evidence that oral anticoagulation with warfarin modifies mortality in patients with elevated BP for secondary prevention.  </p> <p>Ticlopidine, clopidogrel, and newer antiplatelet agents, such as prasugrel and ticagrelor have not been sufficiently evaluated in patients with elevated BP. Newer antithrombotic oral drugs (dabigatran, rivaroxaban, apixaban, and edoxaban) are yet to be tested in patients with high BP. </p> <p><b>Certainty of the evidence</b> </p> <p>Most evidence in this review is associated with low‐certainty evidence. The high risk of bias seemed to be associated with incomplete outcome data and selective reporting in two studies (Huynh and JPPP). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003186-sec-0087" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003186-sec-0087"></div> <h3 class="title" id="CD003186-sec-0088">Implications for practice</h3> <section id="CD003186-sec-0088"> <p>Antiplatelet therapy with acetylsalicylic acid (ASA) for primary prevention in patients with elevated blood pressure (BP) provides a benefit, reduction of the risk of cardiovascular events, which is negated by a harm of similar magnitude: increase in major haemorrhage. </p> <p>For secondary prevention in patients with elevated BP, ASA probably reduces the risk of non‐fatal and all cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events when compared to aspirin in patients with elevated BP for secondary prevention.  </p> <p>There is no evidence that oral anticoagulation with warfarin modifies mortality when compared to ASA in patients with elevated BP for secondary prevention. There was no evidence of a difference for major bleeding events when warfarin was compared to ASA. </p> <p>Ticlopidine, clopidogrel and newer antiplatelet agents such as prasugrel and ticagrelor have not been sufficiently evaluated in patients with high BP. Newer antithrombotic oral drugs such as dabigatran, rivaroxaban, apixaban, and edoxaban are yet to be tested in patients with high BP. </p> </section> <h3 class="title" id="CD003186-sec-0089">Implications for research</h3> <section id="CD003186-sec-0089"> <p>Further trials of antiplatelet therapies in patients with elevated BP are required to identify subgroups in whom benefits outweigh the harms and to determine whether there are differences in the effectiveness of different drugs. Specific attention to the standardised documenting of haemorrhagic events is essential. All strokes should be investigated with computerised tomography to differentiate between those of ischaemic and haemorrhagic origin. There should be standard definition of outcomes and complete reporting of all clinically relevant outcomes (mortality, fatal and non‐fatal cardiovascular events, and major and minor bleeding). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003186-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003186-sec-0008"></div> <div class="table" id="CD003186-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Aspirin compared to placebo for adults with hypertension</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>ASA compared to placebo for adults with hypertension</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were excluded)<br/><b>Settings:</b> outpatients and hospitalised <b>(primary prevention)</b> <br/><b>Intervention:</b> ASA <b>(75 mg, 81 mg, or 100 mg)</b> <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks<sup>*</sup> (95% CI)</b> </p> <p><b>Study population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40.1 per 1000 patients‐year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38.8 per 1000 patients‐year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.97</b> </p> <p>(0.87 to 1.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,794</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13.7 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13.4 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b><br/>(0.82 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,794</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal cardiovascular events</b> </p> <p>Follow‐up: mean 4.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77.0 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49.7 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.63</b><br/>(0.45 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2540 </p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b><sup>a</sup> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7.7 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13.4 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.77</b> </p> <p>(1.34 to 2.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,330 </p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All cardiovascular events</b> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42.8 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37.1 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.86</b> </p> <p>(0.77 to 0.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,794</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><sup>*</sup>The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ASA:</b> acetylsalicylic acid; <b>BP:</b> blood pressure; <b>CI:</b> confidence interval; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>A major bleeding was defined as haemorrhagic stroke, or major blood loss defined as a drop in haemoglobin of &gt; 2 g/dl with adequate hydration, or urgent transfusion with final haemoglobin after equilibration of less than pre‐bleed level, or orthostatic hypotension, or supine BP &lt; 90/60 mmHg.<br/><sup>b</sup>Total mortality and cardiovascular mortality have been downgraded twice (for imprecision, and unclear or high risk of bias).<br/><sup>c</sup>Non‐fatal cardiovascular events have been downgraded twice (for unclear or high risk of bias and outcome reported in only 1 out of 4 included studies).<br/><sup>d</sup>All cardiovascular events have been downgraded twice (for imprecision, and for unclear or high risk of bias).  </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003186-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003186-sec-0009"></div> <section id="CD003186-sec-0010"> <h3 class="title" id="CD003186-sec-0010">Description of the condition</h3> <p>Although systemic (arterial) elevations in blood pressure (BP) result in high intravascular pressure, the main complications of elevated BP, coronary heart disease (CHD), ischaemic stroke and peripheral vascular disease (PVD), are related to thrombosis. The association between elevated BP and risk for stroke and CHD has a linear relationship, with increasing risk for higher BP (<a href="./references#CD003186-bbs2-0085" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335(8693):827-38.">Collins 1990a</a>; <a href="./references#CD003186-bbs2-0086" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet1990;335(8692):765-74.">Collins 1990b</a>; <a href="./references#CD003186-bbs2-0087" title="CollinsR , MacMahonS . Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. British Medical Bulletin1994;50(2):272-98.">Collins 1994</a>). An increase in the diastolic BP by 10 millimetres of mercury (mmHg) is associated with a 33% increase in CHD events and a 50% increase in stroke events (<a href="./references#CD003186-bbs2-0085" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990;335(8693):827-38.">Collins 1990a</a>; <a href="./references#CD003186-bbs2-0087" title="CollinsR , MacMahonS . Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. British Medical Bulletin1994;50(2):272-98.">Collins 1994</a>). In middle and old age, there appears to be a direct relationship between the level of BP and the risk of cardiovascular death without any evidence of a threshold down to a BP as low as 115/75 mmHg (<a href="./references#CD003186-bbs2-0101" title="Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet2002;360:1903-13.">PSC 2002</a>). In accordance with the observational data, BP reduction trials have shown a 16% reduction in CHD and 38% reduction in stroke (<a href="./references#CD003186-bbs2-0086" title="CollinsR , PetoR , MacMahonS , HebertP , FiebachNH , EberleinKA , et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet1990;335(8692):765-74.">Collins 1990b</a>). </p> </section> <section id="CD003186-sec-0011"> <h3 class="title" id="CD003186-sec-0011">Description of the intervention</h3> <p>Some complications related to elevated BP, heart failure (HF) or atrial fibrillation (AF), are themselves associated with thromboembolism (<a href="./references#CD003186-bbs2-0100" title="LipGYH , EdmundsE , BeeversDG . Should patients with hypertension receive antithrombotic therapy?Journal of Internal Medicine2001;249:205-14.">Lip 2001b</a>). Evidence also points towards a prothrombotic or hypercoagulable state conferred by elevated BP, as evident by abnormalities of coagulation (<a href="./references#CD003186-bbs2-0094" title="LeeAJ . The role of rheological and haemostatic factors in hypertension. Journal of Human Hypertension1997;11:767-76.">Lee 1997</a>; <a href="./references#CD003186-bbs2-0096" title="LipGYH , BeeversDG . Abnormalities of rheology and coagulation in hypertension. Journal of Human Hypertension1994;8(9):693-702.">Lip 1994</a>), platelet activation (<a href="./references#CD003186-bbs2-0094" title="LeeAJ . The role of rheological and haemostatic factors in hypertension. Journal of Human Hypertension1997;11:767-76.">Lee 1997</a>; <a href="./references#CD003186-bbs2-0096" title="LipGYH , BeeversDG . Abnormalities of rheology and coagulation in hypertension. Journal of Human Hypertension1994;8(9):693-702.">Lip 1994</a>), and endothelial dysfunction (<a href="./references#CD003186-bbs2-0097" title="LipGYH , BlannAD , JonesAF , LipPL , BeeversDG . Relationship of endothelium, thrombogenesis, and haemorrheology in systemic hypertension to ethnicity and left ventricular hypertrophy. American Journal of Cardiology1997;80(12):1566-71.">Lip 1997</a>; <a href="./references#CD003186-bbs2-0098" title="LipGY , BlannAD . Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation2000;101(3):218-20.">Lip 2000</a>; <a href="./references#CD003186-bbs2-0105" title="VanhouttePM . Endothelial dysfunction in hypertension. Journal of Hypertension. Supplement1996;14(5):S83-93.">Vanhoutte 1996</a>) in such patients. It therefore seems plausible that use of antithrombotic therapy may be of particular benefit in preventing the thrombosis‐related complications of elevated BP (<a href="./references#CD003186-bbs2-0100" title="LipGYH , EdmundsE , BeeversDG . Should patients with hypertension receive antithrombotic therapy?Journal of Internal Medicine2001;249:205-14.">Lip 2001b</a>). </p> </section> <section id="CD003186-sec-0012"> <h3 class="title" id="CD003186-sec-0012">How the intervention might work</h3> <p>The antithrombotic agent, acetylsalicylic acid (ASA), is established as an effective agent for secondary prevention in patients with proven occlusive vascular disease. However, it is not recommended for primary prevention, and it is unclear whether it has a role in patients with an increased risk of thrombotic complications such as those with elevated BP. Warfarin has also been found to be useful as thromboprophylaxis in patients with elevated BP and AF, but if BP remains uncontrolled, such therapy carries significant risk, especially from intracranial haemorrhage (<a href="./references#CD003186-bbs2-0083" title="AguilarMI , HartR , PearceLA . Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD006186. [DOI: 10.1002/14651858.CD006186.pub2]">Aguilar 2009</a>; <a href="./references#CD003186-bbs2-0104" title="SPAF II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet1994;343(8899):687-91.">SPAF‐II 1994</a>). </p> </section> <section id="CD003186-sec-0013"> <h3 class="title" id="CD003186-sec-0013">Why it is important to do this review</h3> <p>The debate over the role of antiplatelet therapy and anticoagulation in patients with high BP in clinical practice is still ongoing. The <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> and <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> focused on Japanese patients in primary prevention.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003186-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003186-sec-0014"></div> <p>To conduct an update of a previously published systematic review of the role of antiplatelet therapy and anticoagulation in patients with elevated blood pressure (BP), including elevations in systolic or diastolic BP alone or together: </p> <p> <ol id="CD003186-list-0001"> <li> <p>to determine whether antiplatelet agents (acetylsalicylic acid (ASA), non‐steroidal anti‐inflammatory drugs (NSAIDs), dipyridamole, clopidogrel, ticlopidine, prasugrel, ticagrelor) reduce total deaths or major thrombotic events or both in these patients when compared to placebo or other active treatment; and </p> </li> <li> <p>to determine whether oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban or edoxaban or other vitamin K antagonist anticoagulants) reduce total deaths or major thromboembolic events or both in these patients when compared to placebo or other active treatment. </p> </li> </ol> </p> <p>It should be noted that patients with atrial fibrillation (AF), heart failure (HF), and pre‐eclampsia are excluded, as they are the subjects of separate Cochrane Reviews (<a href="./references#CD003186-bbs2-0083" title="AguilarMI , HartR , PearceLA . Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database of Systematic Reviews2007, Issue 3. Art. No: CD006186. [DOI: 10.1002/14651858.CD006186.pub2]">Aguilar 2009</a>; <a href="./references#CD003186-bbs2-0089" title="DuleyL , Henderson-SmartDJ , MeherS , KingJF . Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: CD004659. [DOI: 10.1002/14651858.CD004659.pub2]">Duley 2004</a>; <a href="./references#CD003186-bbs2-0099" title="LipGYH , ChungI . Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database of Systematic Reviews2000, Issue 2. Art. No: CD003333. [DOI: 10.1002/14651858.CD003333]">Lip 2001a</a>). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003186-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003186-sec-0015"></div> <section id="CD003186-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003186-sec-0017"> <h4 class="title">Types of studies</h4> <p>Single or double‐blind randomised controlled trials (RCTs) comparing antiplatelet drugs or oral anticoagulation with placebo or active treatment<b> of at least 3 months in duration</b> were included. Cohort‐studies, non‐RCTs, and open‐label studies were excluded. </p> <p>The presence or absence of elevated blood pressure (BP) related target organ damage at baseline, was analysed separately if possible. For example, participants who have had a stroke and have elevated BP represented secondary prevention as compared to studies in individuals who have elevated BP but have no prior vascular disease. </p> <section id="CD003186-sec-0018"> <h5 class="title">Definitions of elevated blood pressure</h5> <p>The reader should note that all definitions of elevated BP, including that used in this review, are arbitrary. The crucial question concerns the question 'who benefits from this treatment?' Whilst the absolute benefit may be expected to increase with the level of BP, since BP is a risk factor for the events to be prevented, the iatrogenic risk (haemorrhage) is also expected to increase with increasing BP. </p> </section> </section> <section id="CD003186-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included patients with at least mild increases in BP or isolated systolic or diastolic increases in BP as defined (for practical reasons) by the WHO‐ISH Guidelines for Management of Hypertension 1999, British Society of Hypertension Guidelines for Management of Hypertension 2004, and/or 2018 European Society of Cardiology (ESC)/European Society of Hypertension (ESH) Guidelines for the management of hypertension (<a href="./references#CD003186-bbs2-0107" title="WHO-ISHGMH. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. Journal of Hypertension1999;17(2):151-83.">WHO‐ISHGMH 1999</a>; <a href="./references#CD003186-bbs2-0108" title="WilliamsB , PoulterNR , BrownMJ , DavisM , McInnesGT , PotterJF , et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ2004;328(7445):926.">Williams 2004</a>; <a href="./references#CD003186-bbs2-0109" title="WilliamsB , ManciaG , SpieringW , Agabiti RoseiE , AziziM , BurnierM , et al, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal2018;39(33):3021-104 . [DOI: 10.1093/eurheartj/ehy339]">Williams 2018</a>). In trials prior to 1999, WHO‐ISH guidelines valid at the time of the study/publication were used and noted in the review (<a href="./references#CD003186-bbs2-0106" title="WHO Guidelines Sub-Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Journal of Hypertension1993;11(9):905-18.">WHO‐ISH 1993</a>). Generally, a systolic BP ≥ 140 mmHg or a diastolic BP ≥ 90 mmHg or both were considered to be elevated and fitted the criteria. </p> <p>We excluded patients with atrial fibrillation (AF), congestive heart failure (HF), pre‐eclampsia, eclampsia, and pulmonary hypertension. </p> </section> <section id="CD003186-sec-0020"> <h4 class="title">Types of interventions</h4> <p>Treatment duration of at least 3 months with antiplatelet agents (acetylsalicylic acid (ASA), non‐steroidal anti‐inflammatory drugs (NSAIDs), dipyridamole, clopidogrel, ticlopidine, prasugrel, ticagrelor) or oral anticoagulants (warfarin, dabigatran, rivaroxaban, apixaban or edoxaban or other vitamin K antagonist anticoagulants) were included. Available data on concomitant treatment were collected, where available. </p> </section> <section id="CD003186-sec-0021"> <h4 class="title">Types of outcome measures</h4> <section id="CD003186-sec-0022"> <h5 class="title">Primary outcomes</h5> <p><b>All‐cause mortality</b> and <b>cardiovascular mortality</b> (stroke, myocardial infarction (MI), sudden death, thromboembolic events). </p> </section> <section id="CD003186-sec-0023"> <h5 class="title">Secondary outcomes</h5> <p><b>All non‐fatal cardiovascular events</b> (stroke, MI, thromboembolic events such as acute coronary syndrome, acute limb ischaemia, pulmonary embolism, deep vein thrombosis), as a composite endpoint. </p> <p><b>All major bleeding events</b> (fatal, non‐fatal) as a composite endpoint. A major bleed was defined as haemorrhagic stroke, or major blood loss defined as a drop in haemoglobin of &gt; 2 g/dl with adequate hydration, or urgent transfusion with final haemoglobin after equilibration of less than pre‐bleed level, or orthostatic hypotension, or supine BP &lt; 90/60 mmHg. </p> </section> <section id="CD003186-sec-0024"> <h5 class="title">Tertiary outcomes </h5> <p><b>All cardiovascular events</b> (sudden death, fatal, non‐fatal: stroke, MI, thromboembolic events, coronary revascularization) as a composite endpoint. Any interaction between risk factors for cardiovascular disease or bleeding, and concomitant treatment were analysed if appropriate data were available. Further details were obtained from trial authors, if possible. </p> </section> </section> </section> <section id="CD003186-sec-0025"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003186-sec-0026"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Hypertension Information Specialist conducted systematic searches in the following databases for RCTs without language or publication status restrictions: </p> <p> <ul id="CD003186-list-0002"> <li> <p>the Cochrane Hypertension Specialised Register via the Cochrane Register of Studies (to 8 January 2021); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 12) via the Cochrane Register of Studies; </p> </li> <li> <p>MEDLINE Ovid (1946 to 8 January 2021);</p> </li> <li> <p>Embase Ovid (1974 to 8 January 2021);</p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (to 8 January 2021); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform via the Cochrane Register of Studies (to 8 January 2021). </p> </li> </ul> </p> <p>The Information Specialist modelled subject strategies for databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying RCTs (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003186-bbs2-0093" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019</a>). We presented search strategies for major databases in <a href="./appendices#CD003186-sec-0093">Appendix 1</a>. </p> </section> <section id="CD003186-sec-0027"> <h4 class="title">Searching other resources</h4> <p>Other sources.</p> <p> <ul id="CD003186-list-0003"> <li> <p>We checked abstracts from national and international hypertension meetings to identify unpublished studies and relevant authors of these studies were contacted to obtain further details. </p> </li> <li> <p>The Cochrane Hypertension Information Specialist searched the Hypertension Specialised Register segment (which includes searches of MEDLINE, Embase, and Epistemonikos for systematic reviews) to retrieve existing systematic reviews relevant to this systematic review, so that we could scan their reference lists for additional trials.  </p> </li> <li> <p>We checked the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. </p> </li> <li> <p>Where necessary, we contacted authors of key papers and abstracts to request additional information about their trials. </p> </li> </ul> </p> </section> </section> <section id="CD003186-sec-0028"> <h3 class="title" id="CD003186-sec-0028">Data collection and analysis</h3> <p> <ul id="CD003186-list-0004"> <li> <p>Two review authors (Eduard Shantsila (ES) and Monika Kozieł‐Siołkowska (MKS)) independently selected trials that met the inclusion criteria. </p> </li> <li> <p>The data extracted included information such as patient characteristics, concomitant treatments, study eligibility, quality, and outcomes. </p> </li> <li> <p>Trial quality criteria: assessment of quality for each trial was made in accordance with guidelines in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> based on adequacy of randomisation, degree of blinding, incomplete outcome reporting, selective outcome reporting, loss to follow‐up, and other bias (<a href="./references#CD003186-bbs2-0092" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.">Higgins 2011</a>). </p> </li> <li> <p>Contacting trialists: for unpublished studies or where data were incomplete in published papers, attempts were made to contact authors or researchers to obtain further details. Where relevant, the drug company was contacted to attempt to obtain unpublished trial data on newer antiplatelet drugs that may have been used in patients with hypertension. </p> </li> <li> <p>Resolution of differences: in the rare instances where the two review authors (ES and MKS) disagreed over the grading and inclusion of the studies, they consulted a third person (Gregory Lip (GL)). </p> </li> <li> <p>Appropriate statistical analyses were used (e.g. fixed‐effect or random‐effects model, testing for heterogeneity, etc.). The outcome measures are reported as odds ratio with 95% confidence intervals. Due to lack of sufficient data, funnel‐plot analyses could not be done for the correction for publication bias. At present, we do not intend to use individual patient data. </p> </li> </ul> </p> <section id="CD003186-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ES and MKS) independently analysed for inclusion the titles and abstracts of all the potential studies we identified as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/unclear) or 'do not retrieve'. If there were any doubts, the third author was asked to arbitrate. We retrieved the full‐text study reports/publication and two review authors independently screened the full‐text and identified studies for inclusion. They also identified and recorded reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion or, if required, we consulted a third person (GL). We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram. </p> </section> <section id="CD003186-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data which was piloted on at least one study in the review. One review author (MKS) extracted study characteristics from included studies. We extracted the following study characteristics. </p> <p> <ul id="CD003186-list-0005"> <li> <p>Methods: study design, total duration of study, details of any 'run in' period, number of study centres and location, study setting, and date of study. </p> </li> <li> <p>Participants: number (N) randomised, N lost to follow‐up/withdrawn, N analysed, mean age, age range, gender, inclusion and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary, secondary, and tertiary outcomes specified and collected, and time points reported. </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (ES and MKS) independently extracted outcome data from included studies. We resolved disagreements by consensus with a provision of involving a third person (GL) would it be required. One review author (MKS) transferred data into the Review Manager (<a href="./references#CD003186-bbs2-0102" title="Review Manager 5 (RevMan 5). Version 5.4. The Cochrane Collaboration, 2020.">Review Manager 2020</a>) file. We double‐checked that data were entered correctly by comparing the data presented in the systematic review with the data extraction form. A second review author (ES) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD003186-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ES and MKS) independently evaluated risk of bias for individual studies using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003186-bbs2-0092" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook.">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another author (GL). We evaluated the risk of bias according to the following domains. </p> <p> <ul id="CD003186-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each source of bias as high, low, or unclear, and included a quote from the study report together with a justification for our judgement in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on risk of bias was related to unpublished data or correspondence with a trialist, we reported this in the risk of bias table. </p> <p>When analysing treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD003186-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data using the Mantel‐Haenszel method. The above mentioned data were presented as odds ratios (OR) with 95% confidence intervals (CIs). </p> </section> <section id="CD003186-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was individual participants in RCTs with parallel design. Participants were individually randomised to intervention groups. Studies with multiple time points or more than two arms were not included. </p> </section> <section id="CD003186-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We communicated with investigators or study sponsors in order to verify principal study characteristics and obtain missing numerical outcome data where possible (e.g. when a study was identified as abstract only).<i> </i>Where this was not possible, and the missing data might introduce serious bias, we examined the impact of including such studies in the overall assessment of results by a sensitivity analysis. </p> </section> <section id="CD003186-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between confidence intervals. We used the I<sup>2</sup> statistic to measure heterogeneity among the trials in each analysis, but acknowledged that there was substantial uncertainty in the value of I<sup>2</sup> when there was only a small number of studies. We also considered the P value from the Chi<sup>2</sup> test. If we identified substantial heterogeneity we reported it and explored possible causes by prespecified subgroup analysis. We defined substantial heterogeneity using a threshold of I<sup>2</sup> 50% or above. </p> </section> <section id="CD003186-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to pool more than 10 trials, we would have designed and evaluated a funnel plot to explore possible small study biases for the primary outcomes. </p> </section> <section id="CD003186-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only where this was meaningful i.e. if the treatments, participants and the underlying clinical question were similar enough for pooling to make sense. </p> <p>We used a fixed‐effect model as the previous updates of the analysis indicated a relatively small number of eligible trials and the same intervention effect could be assumed. </p> </section> <section id="CD003186-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Heterogeneity among trial participants could be related to age or comorbidities. There were insufficient data to carry out subgroup analyses.   </p> </section> <section id="CD003186-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>Due to the small number of included studies, these planned sensitivity analyses were not performed. </p> </section> <section id="CD003186-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We designed a summary of findings table using the following outcomes: total mortality, cardiovascular mortality, non‐fatal cardiovascular events, major bleedings, and all cardiovascular events. The five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) were used to evaluate the certainty of a body of evidence as it relates to the studies which contributed data to the meta‐analyses for the prespecified outcomes. We used methods and recommendations described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003186-bbs2-0103" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Interpreting results and drawing conclusions. In: HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editors(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2017.">Schünemann 2017</a>) using GRADEpro software (<a href="./references#CD003186-bbs2-0091" title="GRADEpro GDT. Version accessed prior to 16 May 2022. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>). We justified all decisions to downgrade the quality of studies using footnotes, and we left comments to aid reader's understanding of the review where necessary.<br/>Judgements about evidence certainty were made by two review authors (ES and MKS) working independently, with disagreements resolved by discussion or involving a third author (GL). Judgements were justified, documented, and incorporated into reporting of results for each outcome.<br/>We extracted study data, formatted our comparisons in data tables, and prepared a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003186-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003186-sec-0041"></div> <section id="CD003186-sec-0042"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD003186-sec-0109" title="">Characteristics of included studies</a>. </p> <section id="CD003186-sec-0043"> <h4 class="title">Results of the search</h4> <p>The January 2021 search identified 3728 potentially relevant publications, of which 2398 records remained after de‐duplication. Of the 2398, 1712 were removed by the Information Specialist after comparison with previously excluded records and the remaining 686 records were screened by the author team (<a href="#CD003186-fig-0001">Figure 1</a>).  </p> <div class="figure" id="CD003186-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram corresponding to the search update (2021)." data-id="CD003186-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/CD003186-FIG-01.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram corresponding to the search update (2021).</p> </div> </div> </div> <p>91 studies were assessed for eligibility in this review. Nine potentially appropriate randomised controlled trials (RCTs) remained. One study had two publications, with two different definitions for elevated blood pressure (BP) used: patients with systolic BP &gt; 145 mmHg (2000 publication), and patients treated with antihypertensive drugs at entry or during the trial (1998 publication) (<a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). Both sets of data reported on different outcomes in hypertensive subgroups. These data were included as much as possible without duplication. </p> <p>Among the other included studies, we tried to obtain further information from the authors. In most studies we were unable to retrieve the data, which was largely due to the length of time since publication of the original trials. However, details were successfully retrieved from two studies (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>). One study had a duplicate publication including a subgroup analysis with a different definition of hypertension, systolic BP &gt; 145 mmHg (2000 publication), than in the data set provided from the original trial, patients on antihypertensive medication at entry or during study (1998 publication) (<a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). Both sets of data have been considered separately. </p> </section> <section id="CD003186-sec-0044"> <h4 class="title">Included studies</h4> <p>We included six studies (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). Two of the trials (<a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>) were new in this update. </p> <section id="CD003186-sec-0045"> <h5 class="title">Participants</h5> <p><a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> included patients from 16 countries in Europe and USA with recent ischaemic stroke, recent myocardial infarction (MI) or symptomatic peripheral vascular disease (PVD). Mean patients' age was 62.5 years. 72% of the patients were males, and 95% of the patients were Caucasians.  </p> <p>In <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>, patients from 26 countries, aged 50 to 80 years (mean 61.5 years) with hypertension and diastolic BP between 100 mmHg and 115 mmHg were enrolled.  </p> <p>In <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>, men aged between 45 and 69 years (mean 57.5 years) at high risk of ischaemic heart disease were recruited from 108 practices in the UK. </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> included patients from Canada with unstable angina or non‐ST‐segment elevation MI, with prior coronary artery bypass grafting (CABG), and who were poor candidates for a revascularisation procedure. Mean age of patients was 67 years. </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> included patients from Japan with type 2 diabetes, aged 30 to 85 years (mean age 65 years) with 55% males.  </p> <p>In the <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>, Japanese patients with atherosclerotic risk factors (hypertension, diabetes mellitus, or dyslipidaemia) were enrolled. Median age was 70 years. 42% of patients were men. </p> </section> <section id="CD003186-sec-0046"> <h5 class="title">Interventions</h5> <p><a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> ‐ acetylsalicylic acid (ASA) versus clopidogrel. </p> <p><a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a> ‐ ASA versus placebo. </p> <p><a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> ‐ ASA versus placebo or warfarin versus placebo. </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> ‐ ASA versus placebo or warfarin versus placebo or ASA versus warfarin. </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> ‐ ASA versus placebo. </p> <p><a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> ‐ ASA versus placebo. </p> </section> <section id="CD003186-sec-0047"> <h5 class="title">Outcomes</h5> <p><a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> ‐ all‐cause mortality (vascular death, MI, ischaemic or haemorrhagic stroke), all‐cause rehospitalisation (hospitalisation for ischaemic events (unstable angina, transient ischaemic attack (TIA), limb ischaemia) or for bleeding events). Non‐fatal events (ischaemic stroke, MI, primary intracranial haemorrhage and leg amputation). </p> <p><a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a> ‐ major cardiovascular events were defined as fatal and non‐fatal MI, fatal and non‐fatal stroke, and other cardiovascular deaths. Silent MI was defined as new Q or QS waves without clinical signs of MI. </p> <p><a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> ‐ fatal and non‐fatal events (i.e. coronary death and fatal and non‐fatal MI). Stroke was a secondary endpoint.  </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> ‐ composite endpoint of all‐cause mortality, MI or unstable angina requiring hospital admission. Other endpoints were coronary revascularisation.  </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> ‐ primary endpoint: any atherosclerotic event (a composite of sudden death from coronary, cerebrovascular, and aortic causes; non‐fatal acute MI; unstable angina; newly developed exertional angina; non‐fatal ischaemic and haemorrhagic stroke; transient ischaemic attack; or non‐fatal aortic and PVD (arteriosclerosis obliterans, aortic dissection, mesenteric arterial thrombosis). Secondary endpoints: each primary endpoint and combinations of primary endpoints and death from any cause. </p> <p><a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> ‐ primary outcome: composite of death from cardiovascular causes (MI, stroke, and other cardiovascular causes), non‐fatal stroke (ischaemic or haemorrhagic, including undefined cerebrovascular events), and non‐fatal MI. The first secondary endpoint: a composite that included the same events as the primary endpoint, plus TIA, angina pectoris, and arteriosclerotic disease requiring surgery or intervention. Other secondary endpoints: death from cardiovascular disease, death from non‐cardiovascular causes, non‐fatal stroke (ischaemic or haemorrhagic), non‐fatal MI, TIA, angina pectoris, arteriosclerotic disease requiring surgery or intervention, and serious extracranial haemorrhage requiring transfusion or hospitalisation. </p> </section> <section id="CD003186-sec-0048"> <h5 class="title">Funding and conflicts of interest</h5> <p><a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> ‐ the study was funded by Sanofi and Bristol‐Myers Squibb. </p> <p><a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a> ‐ the principal sponsor of the HOT Study was Astra AB, Sweden. </p> <p><a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> ‐ funding: Medical Research Council, British Heart Foundation, DuPont Pharma, and Bayer Corporation. GlaxoWellcome and Boehringer‐Ingelheim provided warfarin free of charge during the pilot stage. DuPont Pharma provided warfarin, and Bayer Corporation provided ASA free of charge during the main trial. </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> ‐ no information regarding funding of this study was provided.   </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> ‐ the study was supported by the Ministry of Health, Labour, and Welfare of Japan. </p> <p><a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> ‐ the study was supported by the funds from the Japanese Ministry of Health, Labour, and Welfare, and the Wacksman Foundation of Japan. </p> </section> </section> <section id="CD003186-sec-0049"> <h4 class="title">Excluded studies</h4> <p>See <a href="#CD003186-fig-0001">Figure 1</a>. </p> <p>516 studies were excluded because of the coexistence of atrial fibrillation (AF) or generally lack of suitability of the study and due to lack of randomisation. </p> <p>Among the studies evaluating non‐steroidal anti‐inflammatory drugs (NSAIDs) (including ASA), clopidogrel and ticlopidine, 67 studies were not included for further analysis for various reasons: 39 because of short duration of the studies (less than 3 months) and 12 due to inability to obtain data for the hypertensive subgroup (see <a href="./references#CD003186-sec-0110" title="">Characteristics of excluded studies</a>). </p> <p>Three studies evaluating warfarin were excluded, since detailed data on the hypertensive patients were not available (<a href="./references#CD003186-bbs2-0015" title="O'ConnorCM , GattisWA , HellkampAS , LangerA , LarsenRL , HarringtonRA , et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Infarction Study (CARS). American Journal of Cardiology2001;88(5):541-6. ">CARS 2001</a>; <a href="./references#CD003186-bbs2-0072" title="SPIRIT. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) study group. Annals of Neurology1997;42(6):857-65. ">SPIRIT 1997</a>; <a href="./references#CD003186-bbs2-0081" title="MohrJP , ThompsonJLP , LazarRM , LevinB , SaccoRL , FurieKL , et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. New England Journal of Medicine2001;345:1444-51. ">WARS 2001</a>). One study evaluating rivaroxaban was also excluded due to lack of hypertensive group (<a href="./references#CD003186-bbs2-0010" title="MegaJL , BraunwaldE , WiviottS , BassandJP , BhattDL , BodeC , et al, ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. New England Journal of Medicine2012;366:9-19. ">ATLAS ACS 2‐TIMI 51 2012</a>). Two trials investigating rivaroxaban or ASA or both in secondary prevention had no information on the hypertensive patients despite inclusion of the majority of patients with elevated BP (<a href="./references#CD003186-bbs2-0017" title="EikelboomJW ,  ConnollySJ ,  BoschJ ,  DagenaisGR ,  HartRG ,  ShestakovskaO ,  et al,  COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. New England Journal of Medicine2017;377(14):1319-30. ">COMPASS 2017</a>; <a href="./references#CD003186-bbs2-0053" title="KasnerSE ,  LavadosP ,  SharmaM ,  WangY ,  WangY ,  DávalosA ,  et al,  NAVIGATE ESUS Steering Committee and Investigators. Characterization of patients with Embolic Stroke of Undetermined Source in the NAVIGATE ESUS randomized trial. Journal of Stroke and Cerebrovascular Diseases2018;27(6):1673-82. ">NAVIGATE ESUS 2018</a>). Five studies investigating glycoprotein IIb/IIIa inhibitors or ticlopidine and their impact on cardiovascular and haemorrhagic events lacked sufficient follow‐up data (<a href="./references#CD003186-bbs2-0021" title="ThelMC , CaliffRM , TchengJE , SigmonKN , LincoffAM , TopolEJ , et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. American Heart Journal1999;137(2):264-73. ">EPIC 1999</a>; <a href="./references#CD003186-bbs2-0022" title="KleimanNS , LincoffAM , KereiakesDJ , MillerDP , AguirreFV , AndersonKM , et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation1998;97(19):1912-20. ">EPILOG 1998</a>; <a href="./references#CD003186-bbs2-0025" title="FinelliC , PalaretiG , PoggiM , TorricelliP , VianelliN , FiacchiniM , et al. Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study. Acta Haematologica1991;85(3):113-8. ">Finelli 1991</a>; <a href="./references#CD003186-bbs2-0055" title="NovoS , AbrignaniMG , PavoneG , ZamueliM , PerniceC , GeraciAM , et al. Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. International Angiology1996;15(2):169-74. ">Novo 1996</a>; <a href="./references#CD003186-bbs2-0069" title="SchuhlenH , KastratiA , PacheJ , DirschingerJ , SchomigA . Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. Journal of the American College of Cardiology2001;37(8):2066-73. ">Schuhlen 2001</a>). A further publication was excluded due to the inability to acquire the relevant data (<a href="./references#CD003186-bbs2-0075" title="HassWK , EastonJD , Adams HP Jr, Pryse-PhillipsW , MolonyBA , AndersonS , et al, Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New England Journal of Medicine1989;321:501-7. ">TASS 1998</a>). </p> <p>The CHANCE study (<a href="./references#CD003186-bbs2-0016" title="XuJ , TaoY , LiH , GuH , XieX , MengX , et al. Different levels of blood presure, different benefit from dual antiplatelet therapy in minor stroke or TIA patients. Scientific Reports2017;7:3884. ">CHANCE 2017</a>) compared two drugs (ASA and clopidogrel) versus one drug (ASA) which was not the aim of this review.  </p> <p>The APTC meta‐analysis included mostly secondary prevention trials (142 out of 145) and compared the effects of antiplatelet therapy (at least 1 month duration) to placebo on a composite outcome measure, major vascular events (defined as non‐fatal MI, non‐fatal stroke or vascular deaths). Individual patient data for patients with baseline diastolic BP &gt; 90 mmHg was reported from 29 of the trials (<a href="./references#CD003186-bbs2-0009" title="Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ1994;308(6921):81-106. ">APTC 1994</a>). These trials must have been mostly secondary prevention trials and probably would have met the inclusion criteria of this review. However, several attempts were made to obtain more information from the APTC authors as to the identity of and data from these 29 trials, but no replies were received. </p> <p>Most of the excluded trials were less than 1 month duration, in particular the 5 GPIIb/IIIa inhibitor and ticlopidine trials were only observing the effects over a few days. We did not think that this observational period would be sufficient to make any meaningful statements about the prevention of thromboembolic events in hypertensive patients. Furthermore, the NSAID trials assessed the effects on BP itself rather than thromboembolic complications. </p> </section> </section> <section id="CD003186-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias has been assessed in the corresponding tables and figures (<a href="#CD003186-fig-0002">Figure 2</a>; <a href="#CD003186-fig-0003">Figure 3</a>) section, evaluating the internal validity of each included study. </p> <div class="figure" id="CD003186-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003186-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003186-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003186-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003186-sec-0051"> <h4 class="title">Allocation</h4> <p>Three studies (<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>) gave information about how the randomisation sequence was generated.  </p> <p><a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> had low risk of selection bias. Randomisation: computer‐generated balanced blocks of four treatments with random sequential allocation of drug supplies packaged in predetermined order, each carton containing tablets for four patients. </p> <p><a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a> had also a low risk of selection bias. Computer‐generated randomisation on the basis of baseline characteristics. Patients were stratified for a number of geographic variables. </p> <p><a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> had unclear risk of bias. Randomised controlled trial, although the randomisation sequence generation technique used is not fully described. </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> had unclear risk of bias because of no information regarding the randomisation method. </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> had also unclear risk of bias. The randomisation was performed as non‐stratified randomisation from a random number table. Other details are lacking. The sealed envelopes with random assignments were prepared, and they were sent by email to the physicians from the trial.  </p> <p><a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> had low risk of bias. Pseudo‐random numbers were generated using the Mersenne Twister method with a seed of 4989. The study statistician generated the random allocation sequence using a central computerised system and study physicians were sent the information about treatment via the study website or by fax.  A placebo‐controlled study design was not performed because the Japan Pharmaceutical Affairs Law limits the use of placebo in large, physician‐led studies of approved products such as aspirin. </p> </section> <section id="CD003186-sec-0052"> <h4 class="title">Blinding</h4> <p><a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> had low risk of performance bias. Participants blinded. Blinding procedure is described (blisters packs with placebo tablets were given to patients, and platelet aggregation testing was forbidden). No information is given regarding personnel blinding. A central validation committee validated the reported outcome events unaware of randomisation code and independent statistical centre performed the analysis before randomisation scheme was provided. It had unclear risk of detection bias. Obtained from medical records; review authors do not believe this would introduce bias. However, no information about blinding of outcome assessor is given. </p> <p><a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a> had low risk of performance and detection bias. Patients were randomised in a double‐blinded way to ASA or identical‐looking placebo tablets. Patients randomised in the Study Co‐ordinating Centre (blinded for trial personnel). A clinical event committee evaluated events masked to treatment allocation: review authors do not believe this would introduce bias. </p> <p><a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> had low risk of performance and detection bias. Dose changes were matched on placebo warfarin. Patients were reviewed by their general practitioner (unaware of the allocated study group), records flagged in the NHS central register. Independent assessment of endpoints was carried out. Obtained from medical records: review authors do not believe this would introduce bias. Independent reviewer was unaware of treatment group. </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> had low risk of performance bias. Unblinded pharmacists or physicians, not otherwise involved in the study and patient care, adjusted warfarin to a targeted international normalised ratio (INR) (2.0 to 2.5). To maintain the double‐blinded integrity, patients assigned to placebo therapy had also regular blood tests and mock adjustments. It had an unclear risk of detection bias. Obtained from medical records: review authors do not believe this would introduce bias. However, no information about blinding of outcome assessor is given. </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> had unclear risk of performance and detection bias. Open‐label trial. Study participants were unblinded. Patients were randomly assigned to the ASA group or the non‐ASA group. The randomisation was performed as non‐stratified randomisation from a random number table. The details about study centre and explanation of the term non‐aspirin groups are not provided. The trial is designed with blinded endpoint assessment. However, the way of blinding of outcome assessment is not described. </p> <p><a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> had unclear risk of performance bias and a low risk of detection bias. Patients were reviewed by their general practitioner (unaware of the allocated study group), records flagged in the NHS central register. Independent assessment of endpoints was carried out. Obtained from medical records: review authors do not believe this would introduce bias. Study endpoints were evaluated centrally and biannually by an expert, multidisciplinary event adjudication committee that was blinded to treatment assignments in accordance with the Prospective Randomized Open Blinded Endpoint (PROBE) trial design.  </p> </section> <section id="CD003186-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>) had low risk of attrition bias. </p> <p>In <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>, 0.3% of patients were lost to follow‐up in each group. </p> <p>In <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> only 1.1% of patients were lost to follow‐up.  </p> <p><a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a> had unclear risk of attrition bias. There was a lack of planned statistical power due to the lower than expected incidence of atherosclerotic events. All‐cause mortality was not reported. 193 patients (7.6%) were lost to follow‐up. </p> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> had high risk of attrition bias. The study was terminated prematurely due to difficulty in recruiting because of high rate conventional and investigative procedures although only three patients (2.2% of 135 patients) were lost to follow‐up. </p> <p><a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> had also high risk of attrition bias. 10.5% of patients were lost to follow‐up.   </p> </section> <section id="CD003186-sec-0054"> <h4 class="title">Selective reporting</h4> <p>Four studies (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>) had low risk of bias. All predetermined outcomes were reported.  One study (<a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>) had unclear risk of bias and one (<a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>) had a high risk of reporting bias. </p> <p>Even if they lack selective reporting (all predetermined outcomes were reported), we must keep in mind that we reviewed only published articles. However, studies achieving inconclusive results are unlikely published. </p> <p>Moreover, interpretation and comparisons among trials are difficult as they differ on the defined endpoints. Indeed, endpoints are usually a composite outcome, in which each study group includes different definition. Among the included studies, we tried to obtain further information from the authors. In most studies we were unable to obtain data, which was largely due to the length of time since publication of the original trials. However, details were successfully retrieved from two studies (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>). </p> </section> <section id="CD003186-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> was underpowered by a low event rate to detect a difference between treatment groups. Patients with uncontrolled systemic hypertension were excluded. Moreover, no information is given about how financial support was provided. </p> <p>In <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a> results might have been confounded by a decreasing level of adherence with daily low‐dose ASA in the ASA group (dropping to 76% in year 5) and increasing uptake of daily ASA in the no ASA group (reaching 10% in year 5). Results are limited to Japanese population. </p> <p>Financial support is listed in the 'Included studies' section.</p> </section> </section> <section id="CD003186-sec-0056"> <h3 class="title" id="CD003186-sec-0056">Effects of interventions</h3> <p>See: <a href="./full#CD003186-tbl-0001"><b>Summary of findings 1</b> Aspirin compared to placebo for adults with hypertension</a> </p> <section id="CD003186-sec-0057"> <h4 class="title">1. Primary prevention trials of ASA versus placebo</h4> <p>(<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>) </p> <section id="CD003186-sec-0058"> <h5 class="title">Primary outcome measures</h5> <section id="CD003186-sec-0059"> <h6 class="title">All‐cause mortality</h6> <p>All‐cause mortality was reported in three trials (<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). We were unable to obtain data relating to all‐cause mortality from <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>. The <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> studies showed no evidence of a difference for all‐cause mortality (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.87 to 1.08; 3 studies, 35,794 participants; low‐certainty evidence). </p> </section> <section id="CD003186-sec-0060"> <h6 class="title">Cardiovascular mortality</h6> <p>Cardiovascular mortality was reported in three trials (<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). We were unable to obtain data relating to cardiovascular mortality from <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>. The <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> studies showed no evidence of a difference for cardiovascular mortality (OR 0.98, 95% CI 0.82 to 1.17; 3 studies, 35,794 participants; low‐certainty evidence).  </p> </section> </section> <section id="CD003186-sec-0061"> <h5 class="title">Secondary outcome measures</h5> <section id="CD003186-sec-0062"> <h6 class="title">All non‐fatal cardiovascular events</h6> <p>Total non‐fatal cardiovascular events were reported in one trial (<a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). They were not reported in <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; and <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>. In the <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> study, ASA reduced the risk of all non‐fatal cardiovascular events (OR 0.63, 95% CI 0.45 to 0.87; 1 study, 2540 participants; low‐certainty evidence).  </p> </section> <section id="CD003186-sec-0063"> <h6 class="title">Major bleeding events</h6> <p>Major bleeding events were reported in two trials (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). They were not reported in <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; and <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>. In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a> and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> trials, aspirin increased the risk of major bleeding events (OR 1.77, 95% CI 1.34 to 2.32; 2 studies, 21,330 participants; high‐certainty evidence).  </p> </section> </section> <section id="CD003186-sec-0064"> <h5 class="title">Tertiary outcome measures</h5> <section id="CD003186-sec-0065"> <h6 class="title">All cardiovascular events</h6> <p>Cardiovascular events were evaluated in three studies (<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>). They were not reported in <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>. </p> <p>In the <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> studies, aspirin reduced the risk of all cardiovascular events (OR 0.86, 95% CI 0.77 to 0.96; 3 studies, 35,794 participants; low‐certainty evidence). </p> </section> </section> </section> <section id="CD003186-sec-0066"> <h4 class="title">2. ASA versus clopidogrel; secondary prevention trial</h4> <p>(<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>) </p> <section id="CD003186-sec-0067"> <h5 class="title">Primary outcome measures</h5> <section id="CD003186-sec-0068"> <h6 class="title">All‐cause mortality</h6> <p>In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a><b> </b>trial, there was no evidence of a difference for all‐cause mortality (OR 1.02, 95% CI 0.91 to 1.15; 1study, 19,143 participants; high‐certainty evidence).  </p> </section> <section id="CD003186-sec-0069"> <h6 class="title">Cardiovascular mortality</h6> <p>In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a><b> </b>trial, there was no evidence of a difference for cardiovascular mortality (OR 1.08, 95% CI 0.94 to 1.26; 1 study, 19,143 participants; high‐certainty evidence).  </p> </section> </section> <section id="CD003186-sec-0070"> <h5 class="title">Secondary outcome measures</h5> <section id="CD003186-sec-0071"> <h6 class="title">All non‐fatal cardiovascular events</h6> <p>In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a><b> </b>trial, ASA probably reduces the risk of non‐fatal cardiovascular events when compared to clopidogrel (OR 1.10, 95% CI 1.00 to 1.22; 1 study, 19,143 participants; high‐certainty evidence).  </p> </section> <section id="CD003186-sec-0072"> <h6 class="title">Major bleeding events</h6> <p>Clopidogrel increases the risk of major bleeding events when compared to ASA (OR 1.35, 95% CI 1.14 to 1.61; 1 study, 19,143 participants; high‐certainty evidence). </p> </section> </section> <section id="CD003186-sec-0073"> <h5 class="title">Tertiary outcome measures</h5> <section id="CD003186-sec-0074"> <h6 class="title">All cardiovascular events</h6> <p>In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a><b> </b>trial, ASA probably reduces the risk of all cardiovascular events when compared to clopidogrel (OR 1.08, 95% CI 1.00 to 1.17; 1 study, 19,143 participants; high‐certainty evidence).  </p> </section> </section> </section> <section id="CD003186-sec-0075"> <h4 class="title">3. ASA versus warfarin; secondary prevention trial</h4> <p>(<a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>) </p> <section id="CD003186-sec-0076"> <h5 class="title">Primary outcome measures</h5> <p>Data on cardiovascular mortality were not available.</p> <section id="CD003186-sec-0077"> <h6 class="title">All‐cause mortality</h6> <p>In the <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> trial, there was no evidence of a difference for all‐cause mortality (OR 0.98, 95% CI 0.06 to 16.12; 1 study, 91 participants; low‐certainty evidence).  </p> </section> </section> <section id="CD003186-sec-0078"> <h5 class="title">Secondary outcome measures</h5> <p>Data on all non‐fatal cardiovascular events were not available.</p> <section id="CD003186-sec-0079"> <h6 class="title">Major bleeding events</h6> <p>In the <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a><b> </b>trial, there was no evidence of a difference for major bleeding events (OR 0.13, 95% CI 0.01 to 2.60; 1 study, 91 participants; very low‐certainty evidence).  </p> </section> </section> <section id="CD003186-sec-0080"> <h5 class="title">Tertiary outcome measures</h5> <p>Data on all cardiovascular events were not reported.</p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003186-sec-0081" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003186-sec-0081"></div> <section id="CD003186-sec-0082"> <h3 class="title" id="CD003186-sec-0082">Summary of main results</h3> <p>We included six studies (61,015 patients). Four studies were primary (41,695 patients, <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>), and two secondary prevention (19,320 patients, <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>). Four trials (<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>) were placebo‐controlled, and two studies (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>; <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>) included active comparators. The primary analysis in the present review is based on four high‐quality, prospective, randomised, double‐blinded, controlled trials and two prospective, randomised, open‐label, controlled trials with blinded endpoint assessment. Four of these trials evaluated the effects of acetylsalicylic acid (ASA) as compared to placebo (<a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0004" title="SoejimaH , OgawaH , MorimotoT , NakayamaM , OkadaS , UemuraS , et al. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation Journal2012;76(6):1526-32. [DOI: 10.1253/circj.cj-11-1033]">JPAD 2012</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>), whilst one trial compared the effects of ASA, warfarin and ASA plus warfarin (<a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a>). A further trial investigated the outcome of ASA versus clopidogrel (<a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a>).  </p> <p>The <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a>  studies showed no evidence of a difference for all‐cause mortality. The <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> studies showed no evidence of a difference for cardiovascular mortality. In the <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> study, ASA reduced the risk of all non‐fatal cardiovascular events. In the <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> trial, ASA increased the risk of major bleeding events. In the <a href="./references#CD003186-bbs2-0002" title="HanssonL , ZanchettiA , CarruthersSG , DahlofB , ElmfeldtD , JuliusS , et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment randomised trial. Lancet1998;351(9118):1755-62. [DOI: 10.1016/S0140-6736(98)04311-6]">HOT 1998</a>; <a href="./references#CD003186-bbs2-0005" title="AndoK , ShimadaK , YamazakiT , UchiyamaS , UemuraY , IshizukaN , et al, Japanese Primary Prevention Project (JPPP) Study Group. Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks. Journal of Hypertension2019;37(6):1301-7. ">JPPP 2019</a>; and <a href="./references#CD003186-bbs2-0006" title="MeadeTW , BrennanPJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ2000;321(7252):13-7. [DOI: 10.1136/bmj.321.7252.13]The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet1998;351(9098):233-41. [DOI: 10.1016/S0140-6736(97)11475-1]">TPT 1998</a> studies, ASA reduced the risk of all cardiovascular events. See <a href="./full#CD003186-tbl-0001">summary of findings Table 1</a>. </p> <p>In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a><b> </b>trial, there was no evidence of a difference for all‐cause mortality, and cardiovascular mortality. In the <a href="./references#CD003186-bbs2-0001" title="CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996;348(9038):1329-39. [DOI: 10.1016/S0140-6736(96)09457-3]">CAPRIE 1996</a><b> </b>trial, ASA probably reduces the risk of non‐fatal cardiovascular events when compared to clopidogrel. Clopidogrel increases the risk of major bleeding events when compared to ASA. ASA probably reduces the risk of all cardiovascular events when compared to clopidogrel.  </p> <p>In the <a href="./references#CD003186-bbs2-0003" title="HuynhT , TherouxP , BogartyP , NasmithJ , SolymossS . Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation2001;103:3069-74. [DOI: 10.1161/01.CIR.103.25.3069]">Huynh 2001</a> trial, there was no evidence of a difference for all‐cause mortality, and major bleeding events. </p> <p>The benefits and harms of the newer drugs glycoprotein IIb/IIIa inhibitors, clopidogrel, prasugrel, ticagrelor and oral antithrombotic agents (dabigatran, apixaban, edoxaban, and rivaroxaban) for patients with high blood pressure (BP) have not been studied in clinical trials. </p> <p>Further randomised controlled trials (RCTs) of antithrombotic therapy including newer agents and complete documentation of all benefits and harms are required in patients with elevated BP. </p> </section> <section id="CD003186-sec-0083"> <h3 class="title" id="CD003186-sec-0083">Overall completeness and applicability of evidence</h3> <p>Antiplatelet data were mostly limited to ASA. There were no data available from subgroup analyses of patients with elevated BP treated with glycoprotein IIb/IIIa inhibitors. However, oral glycoprotein IIb/IIIa inhibitors have failed to demonstrate an advantage over ASA after percutaneous coronary revascularisation (<a href="./references#CD003186-bbs2-0090" title="O'NeillWW , SerruysP , KnudtsonM , vanEsGA , TimmisGC , van derZwaanC , et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. New England Journal of Medicine2000;342(18):1316-24.">EXCITE 2000</a>). These patients are at high risk of thromboembolic events. </p> <p>There are no data available with newer antiplatelets (i.e. prasugrel, ticagrelor) or oral anticoagulants (i.e. dabigatran, rivaroxaban, apixaban, edoxaban) as these have not been tested as yet in patients with elevated BP. </p> </section> <section id="CD003186-sec-0084"> <h3 class="title" id="CD003186-sec-0084">Quality of the evidence</h3> <p>Six studies were RCTs, but contributed to the certainty of the evidence with some limitations. </p> <p>For ASA versus placebo, we downgraded total mortality and cardiovascular mortality twice (once for imprecision, and once for risk of bias due to incomplete outcome and reporting bias).  </p> <p>Non‐fatal cardiovascular events have been downgraded twice (for risk of bias due to small sample size and reported only in one study). All cardiovascular events have been downgraded twice (for imprecision, and for risk of bias due to incomplete outcome and reporting bias).  </p> <p>For ASA versus clopidogrel, we assessed GRADE as high certainty for all‐cause mortality, cardiovascular mortality, all non‐fatal cardiovascular events, major bleeding events, and all cardiovascular events. </p> <p>For ASA versus warfarin we downgraded all‐cause mortality, and major bleeding events thrice (for imprecision due to low event rate, high risk of attrition bias, study terminated early, and small sample size).   </p> </section> <section id="CD003186-sec-0085"> <h3 class="title" id="CD003186-sec-0085">Potential biases in the review process</h3> <p>The probability that all used methods (e.g. searching, study selection, data collection, and analysis) could have introduced bias is low. </p> </section> <section id="CD003186-sec-0086"> <h3 class="title" id="CD003186-sec-0086">Agreements and disagreements with other studies or reviews</h3> <p>The Antithrombotic Trialists (ATT) Collaboration 2009 (<a href="./references#CD003186-bbs2-0084" title="Antithrombotic Trialists' (ATT) Collaboration, Colin Baigent,  Lisa Blackwell,  Rory Collins,  Jonathan Emberson,  Jon Godwin,  et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373(9678):1849-60.">ATT Collaboration 2009</a>) assessed the benefits and risks of ASA in the primary and secondary prevention of vascular disease. The analysis involved 18,790 men and women with diastolic BP 100 to 115 mmHg who received 75 mg ASA daily or placebo. The main outcomes were defined as vascular event (myocardial infarction, stroke, or death from a vascular cause including sudden death, pulmonary embolism, haemorrhage). In the primary prevention trials, ASA was associated with a 12% proportional reduction in vascular events (0.51% ASA versus 0.57% control per year, P = 0.0001), due to a reduction of about a fifth in non‐fatal myocardial infarction (0.18% versus 0.23% per year, P &lt; 0.0001). ASA did not reduce the risk of stroke (0.20% versus 0.21% per year, P = 0.4: haemorrhagic stroke 0.04% versus 0.03%, P = 0.05; other stroke 0.16% versus 0.18% per year, P = 0.08).<br/>ASA did not modify vascular mortality. ASA increased major gastrointestinal and extracranial bleeds (0.10% versus 0.07% per year, P &lt; 0.0001). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003186-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram corresponding to the search update (2021)." data-id="CD003186-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/CD003186-FIG-01.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram corresponding to the search update (2021).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/CD003186-FIG-01.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003186-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003186-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA vs placebo, Outcome 1: Total mortality" data-id="CD003186-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: ASA vs placebo, Outcome 1: Total mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA vs placebo, Outcome 2: Cardiovascular mortality" data-id="CD003186-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: ASA vs placebo, Outcome 2: Cardiovascular mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA vs placebo, Outcome 3: Non‐fatal cardiovascular events" data-id="CD003186-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: ASA vs placebo, Outcome 3: Non‐fatal cardiovascular events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA vs placebo, Outcome 4: Major bleedings" data-id="CD003186-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: ASA vs placebo, Outcome 4: Major bleedings</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: ASA vs placebo, Outcome 5: All cardiovascular events" data-id="CD003186-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: ASA vs placebo, Outcome 5: All cardiovascular events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA vs clopidogrel, Outcome 1: Total mortality" data-id="CD003186-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: ASA vs clopidogrel, Outcome 1: Total mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA vs clopidogrel, Outcome 2: Cardiovascular mortality" data-id="CD003186-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: ASA vs clopidogrel, Outcome 2: Cardiovascular mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA vs clopidogrel, Outcome 3: Non‐fatal cardiovascular events" data-id="CD003186-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: ASA vs clopidogrel, Outcome 3: Non‐fatal cardiovascular events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA vs clopidogrel, Outcome 4: All cardiovascular events" data-id="CD003186-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: ASA vs clopidogrel, Outcome 4: All cardiovascular events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: ASA vs clopidogrel, Outcome 5: Major bleeding events" data-id="CD003186-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: ASA vs clopidogrel, Outcome 5: Major bleeding events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA vs warfarin, Outcome 1: Total mortality" data-id="CD003186-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: ASA vs warfarin, Outcome 1: Total mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003186-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/urn:x-wiley:14651858:media:CD003186:CD003186-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: ASA vs warfarin, Outcome 2: Major bleedings" data-id="CD003186-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_t/tCD003186-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: ASA vs warfarin, Outcome 2: Major bleedings</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/media/CDSR/CD003186/image_n/nCD003186-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003186-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Aspirin compared to placebo for adults with hypertension</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>ASA compared to placebo for adults with hypertension</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with hypertension (patients with atrial fibrillation, congestive heart failure, pre‐eclampsia or pulmonary hypertension were excluded)<br/><b>Settings:</b> outpatients and hospitalised <b>(primary prevention)</b> <br/><b>Intervention:</b> ASA <b>(75 mg, 81 mg, or 100 mg)</b> <br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks<sup>*</sup> (95% CI)</b> </p> <p><b>Study population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ASA</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total mortality</b> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40.1 per 1000 patients‐year</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>38.8 per 1000 patients‐year</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.97</b> </p> <p>(0.87 to 1.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,794</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cardiovascular mortality</b> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13.7 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13.4 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.98</b><br/>(0.82 to 1.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,794</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal cardiovascular events</b> </p> <p>Follow‐up: mean 4.4 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77.0 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49.7 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.63</b><br/>(0.45 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2540 </p> <p>(1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Major bleeding</b><sup>a</sup> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7.7 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13.4 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.77</b> </p> <p>(1.34 to 2.32)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,330 </p> <p>(2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/><b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All cardiovascular events</b> </p> <p>Follow‐up: mean 3.8 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42.8 per 1000 patients‐years</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37.1 per 1000 patients‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.86</b> </p> <p>(0.77 to 0.96)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,794</p> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><sup>*</sup>The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>ASA:</b> acetylsalicylic acid; <b>BP:</b> blood pressure; <b>CI:</b> confidence interval; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>A major bleeding was defined as haemorrhagic stroke, or major blood loss defined as a drop in haemoglobin of &gt; 2 g/dl with adequate hydration, or urgent transfusion with final haemoglobin after equilibration of less than pre‐bleed level, or orthostatic hypotension, or supine BP &lt; 90/60 mmHg.<br/><sup>b</sup>Total mortality and cardiovascular mortality have been downgraded twice (for imprecision, and unclear or high risk of bias).<br/><sup>c</sup>Non‐fatal cardiovascular events have been downgraded twice (for unclear or high risk of bias and outcome reported in only 1 out of 4 included studies).<br/><sup>d</sup>All cardiovascular events have been downgraded twice (for imprecision, and for unclear or high risk of bias).  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Aspirin compared to placebo for adults with hypertension</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/full#CD003186-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003186-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ASA vs placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.82, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Non‐fatal cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2540</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.45, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.34, 2.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 All cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.77, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">ASA vs placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003186-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ASA vs clopidogrel</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Cardiovascular mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.94, 1.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Non‐fatal cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [1.00, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [1.00, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Major bleeding events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.14, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">ASA vs clopidogrel</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003186-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ASA vs warfarin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Total mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.06, 16.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Major bleedings <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">ASA vs warfarin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003186.pub4/references#CD003186-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003186.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD003186-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD003186-note-0015">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003186-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003186-note-0014">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003186-note-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD003186-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD003186-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD003186-note-0008">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD003186-note-0007">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD003186-note-0009">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003186-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003186-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003186\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003186\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003186\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003186\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003186\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=XwNPMGod&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003186.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003186.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003186.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003186.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003186.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740713916840"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003186.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740713916844"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003186.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d61d9ac24937a',t:'MTc0MDcxMzkxNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 